Fig. 3: SWOT analysis of live-attenuated MeV as vaccine platform technology.
From: Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines
Depicted are strength, weaknesses, opportunities and threats of the use of live-attenuated recombinant MeV as platform technology to generate vaccines against other pathogens. LMICs low- and middle-income countries, IP intellectual property, Ag antigen, VLPs virus-like particles, GMO genetically modified organism.
